Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

NCT07718854 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Clear Cell Carcinoma
Metastatic Ovarian Cancer
Recurrent Ovarian Clear Cell Adenocarcinoma

Interventions

DRUG: Sacituzumab tirumotecan
DRUG: Pembrolizumab

Sponsor

Tufts Medical Center